CRISPR, Evercore and CRSP

Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As of January 28,
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99
CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target
Crispr Therapeutics AG (CRSP) Gets a Sell from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare company's latest quarterly earnings report,
CRISPR Therapeutics stock rises following analyst upgrade
CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 gene-editing platform,
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
pharmaphorum25d
Vertex and CRISPR Therapeutics to collaborate on genetic disease research
Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...